百力司康

Bliss Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the discovery and development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary Bliss-ADC platform to engineer therapies with improved stability, safety, and efficacy profiles compared to traditional ADCs. Its lead candidate, BB-1701, is a HER2-targeting ADC currently in Phase 2 clinical trials for various solid tumors, including breast and lung cancer. Bliss Biopharmaceutical has established significant global partnerships, most notably a strategic collaboration with Eisai to co-develop and commercialize its lead assets. The company's pipeline also includes programs targeting TROP2, Nectin-4, and other validated oncology targets.